Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 921-930

  Generali, Daniele ^a,b   Fox, Stephen B ^a   Berruti, Alfredo ^d   Brizzi, Maria P ^d   Campo, Leticia ^a   Bonardi, Simone ^b   Wigfield, Simon M ^a   Bruzzi, Paolo ^e   Bersiga, Alessandra ^c   Allevi, Giovanni ^b   Milani, Manuela ^b   Aguggini, Sergio ^b   Dogliotti, Luigi ^d   Bottini, Alberto ^b   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Unità di Patologia Mammaria Breast Cancer Unit   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CARBONIC ANHYDRASES; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 33751111993     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01216     Document Type: Article

References (37)

1. Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V, Harris AL, Pastorek J & Pastorekova S 2002 Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. Journal of Pathology 197 314-321.
2. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P & Harris AL 2001 Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Research 61 5262-5267.
3. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F et al. 2000 p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clinical Cancer Research 6 2751-2758.
4. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B et al. 2005 Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocrine-Related Cancer 12 383-392.
5. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA et al. 2004 Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. Journal of Urology 171 2461-2466.
6. Chia SK & Yorida E 2004 Carbonic anhydrase IX (CaIX) is an independent poor prognostic factor in early stage breast cancer: results from a large population-based tissue microarray (TMA) series. Proceedings of the 27th San Antonio Breast Cancer Symposium. Abstract 3015.
7. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P & Harris AL 2001 Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of Clinical Oncology 19 3660-3668.
8. Christianson DW & Cox JD 1999 Catalysis by metal-activated hydroxide in zinc and manganese metalloenzymes. Annual Reviews in Biochemistry 68 33-57.
9. Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY & Van Marck EA 2003 The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Research and Treatment 81 137-147.
10. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC & Watson PH 2004 Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clinical Cancer Research 10 8720-8727.
11. Coradini D, Pellizzaro C, Speranza A & Daidone MG 2004 Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cellular and Molecular Life Sciences 61 76-82.
12. Dowsett M, Johnston SR, Iveson TJ & Smith IE 1995 Response to specific anti-oestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 525.
13. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 403-410.
14. Gerweck LE & Seetharaman K 1996 Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Research 56 1194-1198.
15. Gillies D 1978 Intracellular pH: methods and applications. Current Topics in Bioenergetics 9 63-87.
16. Harris AL 2002 Hypoxia - a key regulatory factor in tumour growth. Nature Reviews Cancer 2 38-47.
17. Hockel M & Vaupel P 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93 266-276.
18. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U & Vaupel P 1996 Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56 4509-4515.
19. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP et al. 2002 Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research 8 2595-2604.
20. Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L & James ND 2004 Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports 11 1005-1010.
21. Kaluzova M, Kaluz S, Lerman MI & Stanbridge EJ 2004 DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and down-regulation of the hypoxia marker carbonic anhydrase IX. Molecular and Cellular Biology 24 5757-5766.
22. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC & Harris AL 2001 Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clinical Cancer Research 7 3399-3403.
23. Leek RD, Landers RJ, Harris AL & Lewis CE 1999 Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. British Journal of Cancer 79 991-995.
24. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ & West CM 2001 Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Research 61 6394-6399.
25. McCarty KS Jr, Miller LS, Cox EB, Konrath J & McCarty KS, Sr 1985 Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives in Pathology and Laboratory Medicine 109 716-721.
26. Pastorekova S, Zavadova Z, Kostal M, Babusikova O & Zavada J 1992 A novel quasi-viral agent, MaTu, is a two-component system. Virology 187 620-626.
27. Potter CP & Harris AL 2003 Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. British Journal of Cancer 89 2-7.
28. Raghunand N & Gillies RJ 2001 pH and chemotherapy. Novartis Foundation Symposium 240 199-211 (discussion 265-268).
29. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM & Gillies RJ 1999 Enhancement of chemotherapy by manipulation of tumour pH. British Journal of Cancer 80 1005-1011.
30. Roos A 1978 Weak acids, weak bases and intracellular pH. Respiratory Physiology 33 27-30.
31. Schmid T, Zhou J & Brune B 2004 HIF-1 and p53: communication of transcription factors under hypoxia. Journal of Cellular and Molecular Medicine 8 423-431.
32. Span PN, Bussink J, Manders P, Beex LV & Sweep CG 2003 Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. British Journal of Cancer 89 271-276.
33. Supuran CT, Vullo D, Manole G, Casini A & Scozzafava A 2004 Designing of novel carbonic anhydrase inhibitors and activators. Current Medicinal Chemistry Cardiovascular & Hematological Agents 2 51-70.
34. Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J et al. 2004 Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Letters 577 439-445.
35. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL & O'Byrne KJ 2003 Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Journal of Clinical Oncology 21 473-482.
36. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH et al. 2000 Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Research 60 7075-7083.
37. Zambetti M, Giacobone A, Terenziani M, Zucchinelli P, Demicheli R, Biasi S, Piotti P, Bartoli C, Valagussa P & Bonadonna G 1997 Sequential adriamycin and CMF in metastatic breast cancer. Oncologist 2 223-227.